Ying Ruoyan, Yang Jinghui, Wu Xiaocui, Yu Fangyou, Sha Wei
Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China.
Tuberculosis Center for Diagnosis and Treatment, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China.
Microbiol Spectr. 2023 Feb 21;11(2):e0254922. doi: 10.1128/spectrum.02549-22.
Given the increased incidence and prevalence of nontuberculous mycobacterial (NTM) diseases and the natural resistance of NTM to multiple antibiotics, susceptibility testing of different NTM species against drugs from the MYCO test system and new applied drugs is required. A total of 241 NTM clinical isolates were analyzed, including 181 slowly growing mycobacteria (SGM) and 60 rapidly growing mycobacteria (RGM). The Sensititre SLOMYCO and RAPMYCO panels were used for testing susceptibility to commonly used anti-NTM antibiotics. Furthermore, MIC distributions were determined against 8 potential anti-NTM drugs, including vancomycin (VAN), bedaquiline (BDQ), delamanid (DLM), faropenem (FAR), meropenem (MEM), clofazimine (CLO), cefoperazone-avibactam (CFP-AVI), and cefoxitin (FOX), and epidemiological cutoff values (ECOFFs) were analyzed using ECOFFinder. The results showed that most of the SGM strains were susceptible to amikacin (AMK), clarithromycin (CLA), and rifabutin (RFB) from the SLOMYCO panels and BDQ and CLO from the 8 applied drugs, while RGM strains were susceptible to tigecycline (TGC) from the RAPMYCO panels and also BDQ and CLO. The ECOFFs of CLO were 0.25, 0.25, 0.5, and 1 μg/mL for the mycobacteria M. kansasii, M. avium, M. intracellulare, and M. abscessus, respectively, and the ECOFF of BDQ was 0.5 μg/mL for the same four prevalent NTM species. Due to the weak activity of the other 6 drugs, no ECOFF was determined. This study on the susceptibility of NTM includes 8 potential anti-NTM drugs and a large sample size of Shanghai clinical isolates and demonstrates that BDQ and CLO had efficient activities against different NTM species , which can be applied to the treatment of NTM diseases. We designed customized panel that contains 8 repurposed drugs, including vancomycin (VAN), bedaquiline (BDQ), delamanid (DLM), faropenem (FAR), meropenem (MEM), clofazimine (CLO), cefoperazone-avibactam (CFP-AVI), and cefoxitin (FOX) from the MYCO test system. To better understand the efficacy of these 8 drugs against different NTM species, we determined the MICs of 241 NTM isolates collected in Shanghai, China. We attempted to define the tentative epidemiological cutoff values (ECOFFs) for the most prevalent NTM species, which is an important factor in setting up the breakpoint for a drug susceptibility testing. We used the MYCO test system as an automatic quantitative drug sensitivity test of NTM and extended the method to BDQ and CLO in this study. The MYCO test system complements commercial microdilution systems that currently lack BDQ and CLO detection.
鉴于非结核分枝杆菌(NTM)疾病的发病率和患病率不断上升,以及NTM对多种抗生素的天然耐药性,需要对不同NTM菌种进行针对MYCO检测系统中的药物和新应用药物的药敏试验。共分析了241株NTM临床分离株,包括181株缓慢生长分枝杆菌(SGM)和60株快速生长分枝杆菌(RGM)。使用Sensititre SLOMYCO和RAPMYCO板检测对常用抗NTM抗生素的敏感性。此外,还测定了针对8种潜在抗NTM药物的最低抑菌浓度(MIC)分布,这些药物包括万古霉素(VAN)、贝达喹啉(BDQ)、地拉曼id(DLM)、法罗培南(FAR)、美罗培南(MEM)、氯法齐明(CLO)、头孢哌酮-阿维巴坦(CFP-AVI)和头孢西丁(FOX),并使用ECOFFinder分析了流行病学临界值(ECOFFs)。结果显示,大多数SGM菌株对SLOMYCO板中的阿米卡星(AMK)、克拉霉素(CLA)和利福布汀(RFB)以及8种应用药物中的BDQ和CLO敏感,而RGM菌株对RAPMYCO板中的替加环素(TGC)以及BDQ和CLO敏感。对于堪萨斯分枝杆菌、鸟分枝杆菌、胞内分枝杆菌和脓肿分枝杆菌,CLO的ECOFFs分别为0.25、0.25、0.5和1μg/mL,对于相同的四种常见NTM菌种,BDQ的ECOFF为0.5μg/mL。由于其他6种药物的活性较弱,未确定ECOFF。这项关于NTM药敏性的研究包括8种潜在抗NTM药物以及大量来自上海的临床分离株样本,并表明BDQ和CLO对不同NTM菌种具有有效的活性,可应用于NTM疾病的治疗。我们设计了定制板,其中包含8种重新利用的药物,包括来自MYCO检测系统的万古霉素(VAN)、贝达喹啉(BDQ)、地拉曼id(DLM)、法罗培南(FAR)、美罗培南(MEM)、氯法齐明(CLO)、头孢哌酮-阿维巴坦(CFP-AVI)和头孢西丁(FOX)。为了更好地了解这8种药物对不同NTM菌种的疗效,我们测定了在中国上海收集的241株NTM分离株的MICs。我们试图为最常见的NTM菌种定义暂定的流行病学临界值(ECOFFs),这是设定药敏试验断点的一个重要因素。在本研究中,我们使用MYCO检测系统作为NTM的自动定量药敏试验,并将该方法扩展到BDQ和CLO。MYCO检测系统补充了目前缺乏BDQ和CLO检测的商业微量稀释系统。